Bediou Benoit, Brunelin Jérôme, d'Amato Thierry, Fecteau Shirley, Saoud Mohamed, Hénaff Marie-Anne, Krolak-Salmon Pierre
Université de Lyon Lyon, France.
Front Psychol. 2012 Apr 3;3:98. doi: 10.3389/fpsyg.2012.00098. eCollection 2012.
Patients suffering from various neurological and psychiatric disorders show different levels of facial emotion recognition (FER) impairment, sometimes from the early phases of the disease. Investigating the relative severity of deficits in FER across different clinical and high-risk populations has potential implications for the diagnosis and treatment of these diseases, and could also allow us to understand the neurobiological mechanisms of emotion perception itself. To investigate the role of the dopaminergic system and of the frontotemporal network in FER, we reanalyzed and compared data from four of our previous studies investigating FER performance in patients with frontotemporal dysfunctions and/or dopaminergic system abnormalities at different stages. The performance of patients was compared to the performance obtained by a specific group of matched healthy controls using Cohen's d effect size. We thus compared emotion and gender recognition in patients with frontotemporal dementia (FTD), amnestic mild cognitive impairment (aMCI), Alzheimer's disease (AD) at the mild dementia stage, major depressive disorder, Parkinson's disease treated by l-DOPA (PD-ON) or not (PD-OFF), remitted schizophrenia (SCZ-rem), first-episode schizophrenia treated by antipsychotic medication (SCZ-ON), and drug-naïve first-episode schizophrenia (SCZ-OFF), as well as in unaffected siblings of patients with schizophrenia (SIB). The analyses revealed a pattern of differential impairment of emotion (but not gender) recognition across pathological conditions. On the one hand, dopaminergic medication seems not to modify the moderate deficits observed in SCZ and PD groups (ON vs. OFF), suggesting that the deficit is independent from the dopaminergic system. On the other hand, the observed increase in effect size of the deficit among the aMCI, AD, and FTD groups (and also among the SIB and SCZ-rem groups) suggests that the deficit is dependent on neurodegeneration of the frontotemporal neural networks. Our transnosographic approach combining clinical and high-risk populations with the impact of medication provides new information on the trajectory of impaired emotion perception in neuropsychiatric conditions, and on the role of the dopaminergic system and the frontotemporal network in emotion perception.
患有各种神经和精神疾病的患者表现出不同程度的面部情绪识别(FER)障碍,有时在疾病的早期阶段就会出现。研究不同临床和高危人群中FER缺陷的相对严重程度,对这些疾病的诊断和治疗具有潜在意义,还能让我们了解情绪感知本身的神经生物学机制。为了研究多巴胺能系统和额颞叶网络在FER中的作用,我们重新分析并比较了之前四项研究的数据,这些研究调查了不同阶段额颞叶功能障碍和/或多巴胺能系统异常患者的FER表现。使用科恩d效应量,将患者的表现与一组特定的匹配健康对照者的表现进行比较。因此,我们比较了额颞叶痴呆(FTD)、遗忘型轻度认知障碍(aMCI)、轻度痴呆阶段的阿尔茨海默病(AD)、重度抑郁症、接受左旋多巴治疗的帕金森病(PD-ON)或未接受治疗的帕金森病(PD-OFF)、缓解期精神分裂症(SCZ-rem)、接受抗精神病药物治疗的首发精神分裂症(SCZ-ON)以及未服用药物的首发精神分裂症(SCZ-OFF)患者,以及精神分裂症患者的未患病同胞(SIB)在情绪和性别识别方面的表现。分析揭示了不同病理状况下情绪(而非性别)识别的差异损伤模式。一方面,多巴胺能药物似乎并未改变SCZ和PD组(ON与OFF)中观察到的中度缺陷,这表明该缺陷与多巴胺能系统无关。另一方面,在aMCI、AD和FTD组(以及SIB和SCZ-rem组)中观察到的缺陷效应量增加,表明该缺陷依赖于额颞叶神经网络的神经退行性变。我们将临床和高危人群与药物影响相结合的跨疾病诊断方法,为神经精神疾病中情绪感知受损的轨迹以及多巴胺能系统和额颞叶网络在情绪感知中的作用提供了新信息。